Evidence map›Paper›PMID 40303220›Full record

ArticleKidney international reports2025

A Pan-Inhibitor of Phosphate Transporters AP306 in Hemodialysis Patients.

Li Wang, Li Zuo, Ming Shi, Leyi Gu, Kunling Ma, Pei Wang, Yu Wang, Qun Luo, Menghua Chen, Ping Zhang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Li WangDepartment of Nephrology and Institute of Nephrology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Sichuan Clinical Research Centre for Kidney Diseases, Chengdu, Sichuan, China.
Li ZuoDepartment of Nephrology, Peking University People's Hospital, Beijing, China.
Ming ShiDepartment of Nephrology, Blood Purification Center, Renmin Hospital of Wuhan University, Wuhan, China.
Leyi GuMolecular Cell Lab for Kidney Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Kunling MaDepartment of Nephrology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Pei WangDepartment of Nephrology, Blood Purification Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yu WangDepartment of Nephrology, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Qun LuoKidney Disease Center, Ningbo No. 2 Hospital, Ningbo, China.
Menghua ChenDepartment of Nephrology, General Hospital of Ningxia Medical University, Yinchuan, China.
Ping ZhangKidney Disease Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Hongli JiangBlood Purification Center, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Guisen LiDepartment of Nephrology and Institute of Nephrology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Sichuan Clinical Research Centre for Kidney Diseases, Chengdu, Sichuan, China.
Weifeng ZhangClinical Science, Shanghai Alebund Pharmaceuticals Limited, Shanghai, China.
Yingxue Cathy LiuBiometrics, Shanghai Alebund Pharmaceuticals Limited, Shanghai, China.
Qing ZhaoClinical Science, Shanghai Alebund Pharmaceuticals Limited, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hyperphosphatemia in patients undergoing dialysis is not well-controlled. AP306 is a pan-inhibitor of phosphate transporters, designed to block the active uptake of phosphate through the gastrointestinal tract. Methods: In this phase 2 randomized, active-controlled, open-label study, hemodialysis patients with serum phosphate between 5.5 and 9.0 mg/dl were randomized to receive either AP306 or sevelamer carbonate for 12 weeks. The primary outcome was the change in serum phosphate levels from baseline until the therapy ceased. AP306 was initiated at 75 mg and adjusted stepwise to 125 mg and 150 mg orally thrice daily every 4 weeks, to maintain serum phosphate between 3.5 and 5.5 mg/dl. Sevelamer levels were adjusted using the same criteria and frequency. Results: A total of 27 patients were randomized to receive AP306 and 28 to receive sevelamer. At the end-of-treatment, both AP306 and sevelamer resulted in a significant decrease from baseline in serum phosphate by 2.51 mg/dl (95% confidence interval [CI]:-3.07 to -1.92; Conclusion: AP306 monotherapy significantly reduced serum phosphate levels and substantially improved the serum phosphate control rate in hemodialysis patients with hyperphosphatemia. AP306 was safe and well-tolerated.

Indexed as

dialysisend-stage kidney diseasehyperphosphatemiaphosphate transporter

Identifiers

PMID40303220
PMCPMC12034869

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.